148 related articles for article (PubMed ID: 37009821)
1. Recent advances of benzimidazole as anticancer agents.
Venugopal S; Kaur B; Verma A; Wadhwa P; Magan M; Hudda S; Kakoty V
Chem Biol Drug Des; 2023 Aug; 102(2):357-376. PubMed ID: 37009821
[TBL] [Abstract][Full Text] [Related]
2. Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure-Activity Relationship.
Shrivastava N; Naim MJ; Alam MJ; Nawaz F; Ahmed S; Alam O
Arch Pharm (Weinheim); 2017 Jun; 350(6):. PubMed ID: 28544162
[TBL] [Abstract][Full Text] [Related]
3. Recent progress of research on anti-tumor agents using benzimidazole as the structure unit.
Wu K; Peng X; Chen M; Li Y; Tang G; Peng J; Peng Y; Cao X
Chem Biol Drug Des; 2022 May; 99(5):736-757. PubMed ID: 35064629
[TBL] [Abstract][Full Text] [Related]
4. Imidazoles as Potential Anticancer Agents: An Update on Recent Studies.
Sharma P; LaRosa C; Antwi J; Govindarajan R; Werbovetz KA
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299488
[TBL] [Abstract][Full Text] [Related]
5. Cinnamide derived pyrimidine-benzimidazole hybrids as tubulin inhibitors: Synthesis, in silico and cell growth inhibition studies.
Sana S; Reddy VG; Srinivasa Reddy T; Tokala R; Kumar R; Bhargava SK; Shankaraiah N
Bioorg Chem; 2021 May; 110():104765. PubMed ID: 33677248
[TBL] [Abstract][Full Text] [Related]
6. A Review on Modern Approaches to Benzimidazole Synthesis.
Venugopal S; Kaur B; Verma A; Wadhwa P; Sahu SK
Curr Org Synth; 2023; 20(6):595-605. PubMed ID: 36221870
[TBL] [Abstract][Full Text] [Related]
7. Recent Progress of Benzimidazole Hybrids for Anticancer Potential.
Akhtar MJ; Yar MS; Sharma VK; Khan AA; Ali Z; Haider MDR; Pathak A
Curr Med Chem; 2020; 27(35):5970-6014. PubMed ID: 31393240
[TBL] [Abstract][Full Text] [Related]
8. Not all benzimidazole derivatives are microtubule destabilizing agents.
Song IH; Park SJ; Yeom GS; Song KS; Kim T; Nimse SB
Biomed Pharmacother; 2023 Aug; 164():114977. PubMed ID: 37271075
[TBL] [Abstract][Full Text] [Related]
9. Insights into the structure and drug design of benzimidazole derivatives targeting the epidermal growth factor receptor (EGFR).
Abdullah MN; Ali Y; Abd Hamid S
Chem Biol Drug Des; 2022 Dec; 100(6):921-934. PubMed ID: 34651438
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Structurally Diverse Benzimidazole Scaffolds as Potential Chemotherapeutic Agents.
Barasa L; Vemana HP; Surubhotla N; Ha SS; Kong J; Yong A; Croft JL; Dukhande VV; Yoganathan S
Anticancer Agents Med Chem; 2020; 20(3):301-314. PubMed ID: 31746304
[TBL] [Abstract][Full Text] [Related]
11. One-pot double intramolecular homolytic aromatic substitution routes to dialicyclic ring fused imidazobenzimidazolequinones and preliminary analysis of anticancer activity.
Fagan V; Bonham S; Carty MP; Aldabbagh F
Org Biomol Chem; 2010 Jul; 8(14):3149-56. PubMed ID: 20485753
[TBL] [Abstract][Full Text] [Related]
12. Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase.
White AW; Almassy R; Calvert AH; Curtin NJ; Griffin RJ; Hostomsky Z; Maegley K; Newell DR; Srinivasan S; Golding BT
J Med Chem; 2000 Nov; 43(22):4084-97. PubMed ID: 11063605
[TBL] [Abstract][Full Text] [Related]
13. Synthesis, biological evaluation and molecular docking of benzimidazole grafted benzsulfamide-containing pyrazole ring derivatives as novel tubulin polymerization inhibitors.
Wang YT; Shi TQ; Zhu HL; Liu CH
Bioorg Med Chem; 2019 Feb; 27(3):502-515. PubMed ID: 30606674
[TBL] [Abstract][Full Text] [Related]
14. N-substituted benzimidazole acrylonitriles as in vitro tubulin polymerization inhibitors: Synthesis, biological activity and computational analysis.
Perin N; Hok L; Beč A; Persoons L; Vanstreels E; Daelemans D; Vianello R; Hranjec M
Eur J Med Chem; 2021 Feb; 211():113003. PubMed ID: 33248847
[TBL] [Abstract][Full Text] [Related]
15. Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An
Jubie S; Durai U; Latha S; Ayyamperumal S; Wadhwani A; Prabha T
Curr Drug Res Rev; 2021; 13(1):73-83. PubMed ID: 32955008
[TBL] [Abstract][Full Text] [Related]
16. Benzimidazole-based protein kinase inhibitors: Current perspectives in targeted cancer therapy.
Ali AM; Tawfik SS; Mostafa AS; Massoud MAM
Chem Biol Drug Des; 2022 Nov; 100(5):656-673. PubMed ID: 35962624
[TBL] [Abstract][Full Text] [Related]
17. Conjugation of benzylvanillin and benzimidazole structure improves DNA binding with enhanced antileukemic properties.
Al-Mudaris ZA; Majid AS; Ji D; Al-Mudarris BA; Chen SH; Liang PH; Osman H; Jamal Din SK; Abdul Majid AM
PLoS One; 2013; 8(11):e80983. PubMed ID: 24260527
[TBL] [Abstract][Full Text] [Related]
18. Imidazoles and benzimidazoles as tubulin-modulators for anti-cancer therapy.
Torres FC; García-Rubiño ME; Lozano-López C; Kawano DF; Eifler-Lima VL; von Poser GL; Campos JM
Curr Med Chem; 2015; 22(11):1312-23. PubMed ID: 25620093
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents.
Gao C; Li B; Zhang B; Sun Q; Li L; Li X; Chen C; Tan C; Liu H; Jiang Y
Bioorg Med Chem; 2015 Apr; 23(8):1800-7. PubMed ID: 25778766
[TBL] [Abstract][Full Text] [Related]
20. Toxicophoric and metabolic in silico evaluation of benzimidazole and phenylbenzamide derivatives with potential application as anticancer agents.
da Silva VB; Leopoldino AM; Taft CA; da Silva CH
Drug Metab Lett; 2011 Dec; 5(4):267-75. PubMed ID: 22292473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
